HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR)

Atyr PHARMA (NASDAQ:ATYR - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $35.00 target price on the stock.

ATYR has been the subject of a number of other reports. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. Leerink Partners began coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $18.60.

Atyr PHARMA Stock Up 4.1%

ATYR stock traded up $0.21 during midday trading on Wednesday, hitting $5.35. The stock had a trading volume of 3,035,116 shares, compared to its average volume of 1,000,066. The firm has a market cap of $476.17 million, a price-to-earnings ratio of -5.69 and a beta of 0.88. The business has a 50-day moving average of $3.40 and a two-hundred day moving average of $3.49. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $5.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, equities research analysts forecast that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atyr PHARMA

A number of hedge funds have recently made changes to their positions in ATYR. Federated Hermes Inc. purchased a new stake in shares of Atyr PHARMA during the fourth quarter worth about $53,093,000. Point72 Asset Management L.P. bought a new stake in shares of Atyr PHARMA during the fourth quarter valued at approximately $17,677,000. Octagon Capital Advisors LP lifted its holdings in shares of Atyr PHARMA by 294.7% in the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock worth $10,727,000 after buying an additional 2,652,000 shares in the last quarter. Tikvah Management LLC purchased a new position in shares of Atyr PHARMA in the fourth quarter worth $8,908,000. Finally, Woodline Partners LP bought a new position in shares of Atyr PHARMA during the fourth quarter worth $6,092,000. Institutional investors own 61.72% of the company's stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.